title: Osanetant Sanofi-Synthélabo.
abstract: Osanetant is a neurokinin (NK3) receptor antagonist under development by Sanofi-Synthélabo (formerly Sanofi) as a potential treatment for schizophrenia [328910]. Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety [169511]. Following phase IIa clinical trials [307656], [328910], [359231], osanetant entered phase IIb development in February 2001 [409432]. Osanetant was the first potent and selective non-peptide antagonist described for the NK3 tachykinin receptor [176305]. It has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors [176305]. In October 1999, Lehman Brothers predicted that the probability of the product reaching the market was 10%, with a possible launch in 2003 and potential peak sales of US $200 million in 2011 [346267].
authors.affiliation: Wolfson Unit of Clinical Pharmacology, University of Newcastle upon Tyne, Claremont Place, UK. Farhad.Kamali@newcastle.ac.uk
authors.forename: F
authors.initials: F
authors.lastname: Kamali
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D001921:Brain / Q000378:metabolism; D002319:Cardiovascular System / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D010880:Piperidines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D018042:Receptors, Neurokinin-3 / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D015320:Tachykinins / Q000378:metabolism / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D010880:Piperidines; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; C091554:SR 142801; D000109:Acetylcholine; D004298:Dopamine